biologic

Plegridy

peginterferon beta-1a

Loss of exclusivityAugust 2026projected — 12-year biologic exclusivity estimate
CompanyBiogenView the full company profile on CliffBio

Drug detail

Brand namePlegridy
Active ingredientpeginterferon beta-1a
Strength63MCG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Plegridy patent cliff — loss of exclusivity August 2026 | CliffBio